RU58841 helped reduce scalp itching for some users within a week, while others experienced immediate relief. Some users reported initial irritation from the solution, possibly due to the carrier used.
The user added RU58841 to their finasteride and minoxidil routine, noticing significant improvement in hairline after 52 days. Some users warn about potential side effects of RU58841, while others express curiosity and congratulate the progress.
Kintor Pharma announced successful Phase II trial results for KX-826 in treating hair loss, showing it's comparable to finasteride and can be used with it. Some participants saw a 10 hair/cm^2 increase, which is considered a good outcome at the low dose used.
The user was using 1mg finasteride daily and oral minoxidil 2.5mg daily for two years, then added RU58841 to their routine two months ago and is asking for opinions on any changes in hair growth. They provided progress pictures without dermarolling and maintained consistent lighting for comparison.
The post discusses using a combination of Dutasteride, Minoxidil, Ketoconazole, Estradiol, and Spironolactone for hair regrowth. Users suggest it needs more time and possibly a transplant, with some sharing personal experiences and side effects of similar treatments.
Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.
A user started applying 25mg RU58841 daily for hair regrowth and is considering increasing the dosage. They are seeking advice on effective dosages from others who have experienced regrowth with RU58841.
The conversation discusses hair loss treatments, including finasteride, minoxidil, estradiol, and spironolactone, with a focus on their effects on hair regrowth and gender transition. The original poster shares their personal experience with these treatments, emphasizing that estradiol and spironolactone should not be used by those who want to maintain a masculine appearance.
Pyrilutamide is considered by some as an alternative for those avoiding 5AR inhibitors like finasteride and dutasteride, but opinions on its effectiveness vary. Some users report similar results with fluridil and pyrilutamide, while others find pyrilutamide less effective compared to prescription treatments.
The conversation discusses the use of RU58841 for hair loss, focusing on its side effects, standardization issues, and user experiences. The user also inquires about the use of other treatments like minoxidil, finasteride, and microneedling.
KX-826 shows promise for hair maintenance at higher doses with minimal side effects, despite failing Phase III trials. The user believes it is more effective than Minoxidil, Finasteride, and RU58841.
User shared progress with RU 58841, Minox, and Dutasteride 3 times a week for hair loss. Others noticed improvements and expect great gains over the next year.
Eucapil is discussed as a potential hair loss treatment with some believing it to be effective, though its efficacy compared to finasteride is debated. It is considered an anti-androgen treatment, often used alongside other treatments like minoxidil and finasteride, but lacks independent studies to fully support its effectiveness.
The user noticed potential hair growth after 13 days of using RU58841, alongside a regimen of oral minoxidil, finasteride, and topical minoxidil. Others think it's too soon to see results, and some are surprised by the high dosage of oral minoxidil.
User is 16, experiencing hair loss, and using minoxidil and alfatradiol. Shedding decreased, new hairs growing on temples, but unsure if alfatradiol is effective or if future shedding will occur.
The conversation discusses whether hair gained from using Pyrilutamide or RU58841 can be maintained with dutasteride if the former treatments are discontinued. The user prefers oral minoxidil for its effectiveness and convenience over topical applications.
The conversation is about skepticism towards the hair loss treatments RU58841 and Pyrilutamide, with users discussing the lack of human testing for RU58841 and the ongoing trials for Pyrilutamide. Some users believe RU58841 has more anecdotal success, while others highlight Pyrilutamide's current research progress.
Autologous exosome treatment for hair loss is being discussed as an emerging option. Minoxidil, finasteride, and RU58841 are also mentioned as treatments.
The conversation discusses the delay in the release of a new hair loss treatment, Pyrilutamide, and speculates on potential safety concerns as a reason for the delay. It also mentions GT20029 as another future treatment option, with a release at least five years away, and touches on the avoidance of research chemicals due to uncertainty about their authenticity.
The conversation discusses potential new treatments for androgenetic alopecia (AGA), including verteporfin, pyrilutamide, and hair cloning. There is optimism about scientific advancements providing alternatives to minoxidil and finasteride.
A 19-year-old male with no family history of androgenetic alopecia (AGA) is experiencing hair loss and considering using a topical minoxidil and finasteride mixture. Despite low vitamin D levels and normal DHT serum levels, he seeks confirmation of AGA before starting treatment.
The potential risks of long-term use of Dutasteride and how it may be linked to elevated liver enzymes, cholesterol levels, and decreased testosterone. Alternative treatments such as Finasteride and RU58841 were also discussed.
17-alpha-estradiol may work for hair loss by inhibiting 5-alpha reductase, similar to finasteride. It might lower testosterone in the scalp, reducing DHT conversion.
A user shared their successful hair regrowth journey using oral minoxidil, dutasteride, and eucapil, with additional benefits from MTF hormone replacement therapy. They advised consulting specialists and considering individual responses to treatments.
A user's experience with hair loss and scalp inflammation, which was alleviated by using RU58841 along with finasteride and dutasteride. A theory of inflammation possibly being a cause of hairloss is also discussed.
The user is using finasteride, minoxidil, and ciclopirox shampoo for hair loss and is considering adding a topical anti-androgen like RU58841, Clacosterone, or KX286. They have scheduled a hair transplant and are concerned about the cost and effectiveness of future treatments.
The user experienced new hair growth after switching from oral finasteride to topical RU58841 with minoxidil and undergoing stem cell therapy. They noticed new hairs at the hairline and temples, but are unsure which treatment is responsible.
The conversation is about the release of a new phase 3 clinical trial for a year and questioning if the results of the 6-month clinical trials will be shown this quarter. The specific treatment discussed is Pyrilutamide.